Rivipansel flunks Phase III sickle cell trial
The trial was for patients six and older with the disease who required treatment with IV opioids for occlusive crisis.
Read More
Tag: endpoints
Rituxan hits endpoints in late-stage skin disease trial
The drug demonstrated superiority to current standard-of-care to CellCept.
Read More
- NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
- Anocca doses first patients with precision TCR‑T therapy
- Connecta launches phase 2a trial of neuroplasticity modulator
- Aquipta recommended by NICE for acute migraine treatment
- Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
